Prazosin Dosing for Night Terrors and Anxiety

Initial Dosing and Titration

• The American Academy of Sleep Medicine recommends starting with 1 mg at bedtime to minimize risk of first-dose hypotension 1, 2
• Increase by 1-2 mg every few days until clinical response is achieved, as suggested by the American Academy of Sleep Medicine 1, 3
• Initial doses should be lower in elderly patients or those on concurrent antihypertensive medications, according to the American Academy of Sleep Medicine 2

Effective Dose Ranges

• For civilians with PTSD-related nightmares, the average effective dose is approximately 3-4 mg/day, with a mean effective dose of 3.1 ± 1.3 mg, as reported by the American Academy of Sleep Medicine 3, 4
• For military veterans with PTSD-related nightmares, higher doses are often required, with mean effective doses ranging from 9.5-15.6 mg/day, according to the American Academy of Sleep Medicine 3, 5
• For active-duty military personnel, dosing varies by gender, with men requiring a mean effective dose of 15.6 ± 6.0 mg and women requiring a mean effective dose of 7.0 ± 3.5 mg, as suggested by the American Academy of Sleep Medicine 3

Administration Schedule

• Initially, prazosin should be given as a single bedtime dose for nightmare management, as recommended by the American Academy of Sleep Medicine 1
• For more severe cases, especially in military personnel, divided dosing may be considered, according to the American Academy of Sleep Medicine 4

Monitoring and Adjustments

• Monitor blood pressure after initial dose and with each significant dose increase, as suggested by the American Academy of Sleep Medicine 2
• Assess nightmare frequency and intensity using standardized measures when possible, as recommended by the American Academy of Sleep Medicine 1, 3
• If patient is also taking selective serotonin reuptake inhibitors (SSRIs), be aware that the response to prazosin may be diminished, according to the American Academy of Sleep Medicine 4

Common Side Effects and Management

• Dizziness and lightheadedness are common, especially after initial doses, as reported by the American Academy of Sleep Medicine 3, 2
• Transient orthostatic hypotension may occur but usually resolves during treatment, according to the American Academy of Sleep Medicine 3, 5

Special Considerations

• Prazosin appears effective in both civilian and military populations with trauma-related nightmares, as suggested by the American Academy of Sleep Medicine 3
• If prazosin is discontinued, nightmares may return to baseline intensity, according to the American Academy of Sleep Medicine 5

Prazosin Prescription for Night Terrors

Efficacy and Recommendations

• The American Academy of Sleep Medicine gives prazosin a Level A recommendation for PTSD-associated nightmares 6

Alternative Treatment Options

• Clonidine (0.2-0.6 mg in divided doses) can be considered as an alternative to prazosin, although it has less robust evidence and also carries risk of postural hypotension 6

Prazosin Dosing Guidelines for PTSD‑Related Nightmares

1. Recommended Dose Range for Civilians

2. Higher Dose Requirements in Military Veterans

3. Upper Limit Recommended for Most Patients

4. Practical Titration Strategy

5. Safety and Tolerability at Higher Doses

Prazosin as First‑Line Pharmacotherapy for PTSD Nightmares (Evidence from the American Academy of Sleep Medicine and the 2018 VA Trial)

Guideline Recommendation

• The American Academy of Sleep Medicine recommends prazosin as the first‑choice medication for treating PTSD‑related nightmares, stating that “many patients respond very well to prazosin and this agent remains the first choice for pharmacologic therapy,” even though a large 2018 Department of Veterans Affairs (VA) randomized trial did not demonstrate a benefit over placebo. This recommendation reflects a guideline‑level endorsement (Class I, moderate‑quality evidence) for prazosin in civilian and veteran populations with PTSD‑related sleep disturbances. 9

Interaction with Antidepressant Therapy

• In the 2018 VA trial, 78 % of participants were receiving maintenance antidepressants (primarily SSRIs or SNRIs). This high rate of concurrent antidepressant use is thought to have attenuated the therapeutic effect of prazosin, with patients on antidepressants showing markedly smaller improvements in Clinician‑Administered PTSD Scale (CAPS) scores compared with those not on antidepressants. Consequently, clinicians should anticipate a reduced response to prazosin when patients are on SSRIs/SNRIs and may need to titrate to higher doses or consider alternative agents such as topiramate. The evidence derives from a large, multicenter randomized trial (Level A). 9